Eric CHUANG

Eric CHUANG

General Director of Biomedical Technology and Device Research Laboratories

Industrial Technology Research Institute

Eric Y Chuang received his doctorate in cancer biology with toxicology and molecular genetics as two sub-specialties from Harvard University in 1997 and his doctoral thesis was to study radiation-induced mutagenesis in human cells. After graduation, he stayed at Harvard as a postdoctoral fellow for one year. He then joined the Radiation Biology Branch of National Cancer Institute (NCI), National Institutes of Health (NIH) as an IRTA fellow to study radiogenomics in Bethesda, MD, USA. Next, he became the Head of Microarray Laboratory for Radiation Oncology Sciences Program at NCI; his lab was to develop new initiatives that utilized state-of-the-art microarray technologies for studying radiation oncology related research projects. After working at the NIH for several years, he took a faculty position at National Taiwan University (NTU). In 2009, he joined the Radiation Research Program of Division of Cancer Treatment and Diagnosis at NCI as a Program Director to oversee a portfolio of NIH grants that included radiation-induced signaling pathways, molecular mechanisms and normal tissue injuries as well as radiation related genomic studies. In 2011, he returned to NTU and was serving as the Director of Graduate Institute of Biomedical Electronics and Bioinformatics (BEBI) in 2012-2018. Dr. Chuang received his Executive MBA degree in International Business Management from NTU in June 2017. Currently, he is a Professor of BEBI at NTU and serving as the General Director, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan. Being an expert in genomic technologies, bioinformatics, cancer, radiation biology & oncology, biomedical engineering, and precision medicine, he has published more than 160 peer-reviewed papers in related fields. Moreover, Dr. Chuang has been serving as an editorial board member of Scientific Reports and the Editor-in-Chief of Translation Cancer Research.

 Genomic technologies  Cancer genomics  Precision medicine  Bioinformatics  Big data  AI

 2015-2017 EMBA, National Taiwan University, Taipei, Taiwan  1991-1997 Sc.D. Cancer Biology, Harvard University, School of Public Health, Boston, MA  1990-1991 M.S. Biology, Illinois Institute of Technology, Chicago, IL

 Dr. Tung Ta-Cheng’s Basic Cancer Research Award, Taiwan Oncology Society, 2021  The 5th excellent research award on breast cancer, Taiwan Breast Cancer Foundation, 2015  On-the-Spot Award, US Department of Health and Human Services, Public Health Service, 2001

 Daniel T.L Chen, S.W. Cheng, Tiffany Chen, Jane P.C. Chang, B.F. Hwang, H.H. Chang, Eric Y. Chuang, C.H. Chen, K.P. Su, Identification of Genetic Variations in the NAD-Related Pathways for Patients with Major Depressive Disorder: A Case-Control Study in Taiwan, J CLIN MED (impact factor: 4.964, journal ranking: 31%), JUN 23 2022, 11(13):3622, DOI: 10.3390/jcm11133622  Y.P. Hsieh, Y.M. Hung, M.H. Tsai, L.C. Lai, Eric Y. Chuang*, 16S-ITGDB: An Integrated Database for Improving Species Classification of Prokaryotic 16S Ribosomal RNA Sequences, Frontiers in Bioinformatics, AUG 03 2022, 2:905489, DOI: 10.3389/fbinf.2022.905489  H.H. Chao, J.L. Luo, M.H. Hsu, L.H. Chen, T.P. Lu, M.H. Tsai, Eric Y. Chuang, L.L. Chuang, L.C. Lai, Regulatory mechanisms and function of hypoxia-induced long noncoding RNA NDRG1-OT1 in breast cancer cells, CELL DEATH DIS (impact factor: 9.696, journal ranking: 18%), SEP 20 2022, 13(9):807, DOI: 10.1038/s41419-022-05253-2  C.S. Huang, M.L. Tsai, T.P. Lu, C.C. Tu, C.Y. Liu, C.J. Huang, Y.S. Ho, S.H. Tu, Eric Y Chuang, L.M. Tseng, C.C. Huang, The extended concurrent genes signature for disease-free survival in breast cancer, J FORMOS MED ASSOC (impact factor: 3.871, journal ranking: 35%), OCT 01 2022, 121(10):1945-1955, DOI: 10.1016/j.jfma.2022.01.022  A. Chattopadhyay, C.Y. Shih, Y.C. Hsu, J.M. Jimmy Juang, Eric Y. Chuang, T.P. Lu, CLIN_SKAT: an R package to conduct association analysis using functionally relevant variants, BMC BIOINFORMATICS (impact factor: 3.328, journal ranking: 35%), OCT 23 2022, 23(1):441, DOI: 10.1186/s12859-022-04987-2